TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinib.
Wang WX, Xu CW, Chen YP, Liu W, Zhong LH, Chen FF, Zhuang W, Huang YJ, Huang ZZ, Chen RR, Guan YF, Yi X, Lv TF, Zhu WF, Lu JP, Wang XJ, Shi Y, Lin XD, Chen G, Song Y.
Wang WX, et al.
J Thorac Dis. 2018 May;10(5):2991-2998. doi: 10.21037/jtd.2018.04.98.
J Thorac Dis. 2018.
PMID: 29997966
Free PMC article.